Emily Boja
Silver Spring, MD, USA
![Emily Boja.jpeg](https://cbtn-s3.imgix.net/Emily_Boja.jpeg?auto=format&ixlib=react-9.0.3&h=512)
About
Senior Scientist, Office of Chief Scientist
Office of Health Informatics, FDA
Dr. Boja leads the precisionFDA’s biomedical competitions around omics science, as well as outreach activities in building a community of scientists around the analysis of biological datasets to inform regulatory science and advance precision medicine. Prior to joining OHI, she was a Program Director at the Office of Cancer Clinical Proteomic Research, NCI, NIH, who provided scientific expertise and leadership in managing the Clinical Proteomic Tumor Analysis Consortium program.
research
Interests
![Craniopharyngioma.png](https://cbtn-s3.imgix.net/Craniopharyngioma.png?auto=format&ixlib=react-9.0.3&h=200)
Craniopharyngioma
Childhood craniopharyngiomas are rare tumors usually found near the pituitary gland (a pea-sized organ at the bottom of the brain that controls other glands) and the hypothalamus (a small cone-shaped organ connected to the pituitary gland by nerves).Craniopharyngiomas are usually part solid mass and
![Medulloblastoma.png](https://cbtn-s3.imgix.net/Medulloblastoma.png?auto=format&ixlib=react-9.0.3&h=200)
Medulloblastoma
Medulloblastomas comprises the vast majority of pediatric embryonal tumors and by definition arise in the posterior fossa, where they constitute approximately 40% of all posterior fossa tumors. Other forms of embryonal tumors each make up 2% or less of all childhood brain tumors.The clinical feature